No. Too costly and their new business partners have different ideas for success. FUSE says they will release a PR soon to describe the future. I contacted Macular to find out if FUSE/CURE are using them in the future. They won't comment. This implies that FUSE has multiple deals in the works and both companies are not commenting. All this insider BS is closing doors to investors. The insiders still work the system.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.